This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Dismissal of Humira US antitrust case backed by law, economics professors

( December 28, 2020, 19:32 GMT | Official Statement) -- MLex Summary: Plaintiffs seeking to revive US antitrust claims against AbbVie, Amgen, Samsung Bioepis and Sandoz over generic Humira are seeking to disregard existing law by expanding antitrust liability to cover settlements of patent litigation in the biologics and pharmaceuticals spaces that adhere to Supreme Court doctrine and promote consumer welfare, according to a group of law and economics professors. They told a US appeals court the decision to dismiss was a straightforward application of the principles articulated by the Supreme Court in Federal Trade Commission v. Actavis. See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections